The scientist’s investigation covers issues in Cancer research, Pathology, Imatinib mesylate, Imatinib and GiST. Jonathan A. Fletcher has researched Cancer research in several fields, including Carcinogenesis, Proto-Oncogene Proteins c-kit and Receptor tyrosine kinase. His studies deal with areas such as Fluorescence in situ hybridization, Gene rearrangement, Fusion gene and Karyotype as well as Pathology.
His biological study deals with issues like Stromal tumor, which deal with fields such as Survival rate. As a member of one scientific family, Jonathan A. Fletcher mostly works in the field of Imatinib, focusing on Oncology and, on occasion, Surgery. His study in GiST is interdisciplinary in nature, drawing from both Sunitinib, Tyrosine kinase, Protein kinase B and Tyrosine-kinase inhibitor.
His scientific interests lie mostly in Cancer research, Pathology, GiST, Imatinib and Internal medicine. The Cancer research study which covers Receptor tyrosine kinase that intersects with Protein kinase B. The concepts of his Pathology study are interwoven with issues in Fluorescence in situ hybridization, Karyotype and Cytogenetics.
His GiST research incorporates elements of Sunitinib, Immunology, Stromal tumor and Tyrosine-kinase inhibitor. His work in Imatinib tackles topics such as PI3K/AKT/mTOR pathway which are related to areas like MAPK/ERK pathway. He interconnects Gastroenterology, Endocrinology, Surgery and Oncology in the investigation of issues within Internal medicine.
Jonathan A. Fletcher spends much of his time researching Cancer research, GiST, Imatinib, PDGFRA and Pathology. His biological study focuses on Stromal cell. His study looks at the relationship between Stromal cell and fields such as Tyrosine-kinase inhibitor, as well as how they intersect with chemical problems.
His GiST research is multidisciplinary, incorporating elements of Sunitinib, Receptor tyrosine kinase, Stromal tumor and PI3K/AKT/mTOR pathway. His Imatinib study combines topics from a wide range of disciplines, such as Mutation, Drug resistance and Oncology. His biological study spans a wide range of topics, including CDKN2A and Doxorubicin.
His primary areas of investigation include Cancer research, GiST, Imatinib, Imatinib mesylate and Pathology. His Cancer research study integrates concerns from other disciplines, such as Immunohistochemistry, Mutation, Sarcoma, Rhabdomyosarcoma and Cell cycle. In the subject of general GiST, his work in PDGFRA is often linked to Regorafenib, thereby combining diverse domains of study.
His Imatinib study which covers Cancer that intersects with Gerontology. The various areas that Jonathan A. Fletcher examines in his Imatinib mesylate study include Clinical trial, Phases of clinical research, Surgery and Oncology. He has researched Pathology in several fields, including Cell and TFE3.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
George Daniel Demetri;Margaret von Mehren;Charles D. Blanke;Annick Diane Van Den Abbeele.
The New England Journal of Medicine (2002)
The landscape of somatic copy-number alteration across human cancers
Rameen Beroukhim;Craig H. Mermel;Craig H. Mermel;Dale Porter;Guo Wei.
PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors
Michael C. Heinrich;Christopher L. Corless;Anette Duensing;Laura McGreevey.
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Michael C. Heinrich;Christopher L. Corless;George D. Demetri;Charles D. Blanke.
Journal of Clinical Oncology (2003)
Biology of gastrointestinal stromal tumors.
Christopher L. Corless;Jonathan A. Fletcher;Michael C. Heinrich.
Journal of Clinical Oncology (2004)
The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy
Jeffrey S. Ross;Jonathan A. Fletcher.
Stem Cells (1998)
Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT
Charles D Blanke;George D Demetri;Margaret von Mehren;Michael C Heinrich.
Journal of Clinical Oncology (2008)
KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.
Brian P. Rubin;Samuel Singer;Connie Tsao;Anette Duensing.
Cancer Research (2001)
High-throughput oncogene mutation profiling in human cancer
Roman K. Thomas;Alissa C. Baker;Ralph M. DeBiasi;Ralph M. DeBiasi;Wendy Winckler;Wendy Winckler.
Nature Genetics (2007)
PAX8-PPARγ1 Fusion in Oncogene Human Thyroid Carcinoma
Todd G. Kroll;Pasha Sarraf;Lorenza Pecciarini;Chang-Jie Chen.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: